Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price rose 6% during mid-day trading on Wednesday after BMO Capital Markets raised their price target on the stock from $18.00 to $27.00. BMO Capital Markets currently has an outperform rating on the stock. Replimune Group traded as high as $12.41 and last traded at $12.57. Approximately 67,909 shares were traded during trading, a decline of 91% from the average daily volume of 795,967 shares. The stock had previously closed at $11.85.
Several other equities research analysts have also recently issued reports on REPL. Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 24th. Finally, HC Wainwright boosted their price target on shares of Replimune Group from $17.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $19.14.
Get Our Latest Research Report on Replimune Group
Insiders Place Their Bets
In related news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company's stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.
Hedge Funds Weigh In On Replimune Group
Institutional investors have recently bought and sold shares of the business. Point72 DIFC Ltd purchased a new position in Replimune Group during the 2nd quarter worth approximately $57,000. Erste Asset Management GmbH purchased a new position in Replimune Group during the 3rd quarter worth approximately $133,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock valued at $144,000 after purchasing an additional 5,926 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Replimune Group by 81.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock valued at $165,000 after purchasing an additional 6,748 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Replimune Group during the 3rd quarter valued at approximately $222,000. 92.53% of the stock is owned by hedge funds and other institutional investors.
Replimune Group Stock Performance
The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $890.83 million, a PE ratio of -4.27 and a beta of 1.28. The firm's fifty day moving average price is $12.18 and its two-hundred day moving average price is $11.28.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07. As a group, equities research analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current year.
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Featured Articles
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
